122 related articles for article (PubMed ID: 36206607)
21. Predictive value of drug levels, HIV genotyping, and the genotypic inhibitory quotient (GIQ) on response to saquinavir/ritonavir in antiretroviral-experienced HIV-infected patients.
Valer L; de Mendoza C; Soriano V
J Med Virol; 2005 Dec; 77(4):460-4. PubMed ID: 16254964
[TBL] [Abstract][Full Text] [Related]
22. Randomized trial comparing saquinavir soft gelatin capsules versus indinavir as part of triple therapy (CHEESE study).
Cohen Stuart JW; Schuurman R; Burger DM; Koopmans PP; Sprenger HG; Juttmann JR; Richter C; Meenhorst PL; Hoetelmans RM; Kroon FP; Bravenboer B; Hamann D; Boucher CA; Borleffs JC
AIDS; 1999 May; 13(7):F53-8. PubMed ID: 10357371
[TBL] [Abstract][Full Text] [Related]
23. Baseline human immunodeficiency virus type 1 phenotype, genotype, and RNA response after switching from long-term hard-capsule saquinavir to indinavir or soft-gel-capsule saquinavir in AIDS clinical trials group protocol 333.
Para MF; Glidden DV; Coombs RW; Collier AC; Condra JH; Craig C; Bassett R; Leavitt R; Snyder S; McAuliffe V; Boucher C
J Infect Dis; 2000 Sep; 182(3):733-43. PubMed ID: 10950766
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetic characterization of a human immunodeficiency virus protease inhibitor, saquinavir, during ethanol intake in rats.
Shibata N; Kageyama M; Kishida T; Kimura K; Yoshikawa Y; Kuwahara T; Toh J; Shirasaka T; Takada K
Biopharm Drug Dispos; 2003 Nov; 24(8):335-44. PubMed ID: 14595702
[TBL] [Abstract][Full Text] [Related]
25. Baseline antiretroviral drug susceptibility influences treatment response in patients receiving saquinavir-enhancing therapy.
Middleton T; Smith D; Larder B; Law M; Birch C
HIV Clin Trials; 2001; 2(6):445-52. PubMed ID: 11742431
[TBL] [Abstract][Full Text] [Related]
26. Activity of the soft gelatin formulation of saquinavir in combination therapy in antiretroviral-naive patients. NV15355 Study Team.
Mitsuyasu RT; Skolnik PR; Cohen SR; Conway B; Gill MJ; Jensen PC; Pulvirenti JJ; Slater LN; Schooley RT; Thompson MA; Torres RA; Tsoukas CM
AIDS; 1998 Jul; 12(11):F103-9. PubMed ID: 9708399
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetics of once-daily saquinavir hard-gelatin capsules and saquinavir soft-gelatin capsules boosted with ritonavir in HIV-1-infected subjects.
Cardiello PG; Monhaphol T; Mahanontharit A; van Heeswijk RP; Burger D; Hill A; Ruxrungtham K; Lange JM; Cooper DA; Phanuphak P
J Acquir Immune Defic Syndr; 2003 Apr; 32(4):375-9. PubMed ID: 12640194
[TBL] [Abstract][Full Text] [Related]
28. Absence of resistance mutations in antiretroviral-naive patients treated with ritonavir-boosted saquinavir.
Ananworanich J; Hirschel B; Sirivichayakul S; Ubolyam S; Jupimai T; Prasithsirikul W; Chetchotisakd P; Kiertiburanakul S; Munsakul W; Raksakulkarn P; Tansuphasawadikul S; Schutz M; Snowden W; Ruxrungtham K;
Antivir Ther; 2006; 11(5):631-5. PubMed ID: 16964832
[TBL] [Abstract][Full Text] [Related]
29. Double boosted protease inhibitors, saquinavir, and lopinavir/ritonavir, in nucleoside pretreated children at 48 weeks.
Kosalaraksa P; Bunupuradah T; Engchanil C; Boonrak P; Intasan J; Lumbiganon P; Burger D; Ruxrungtham K; Schutz M; Ananworanich J;
Pediatr Infect Dis J; 2008 Jul; 27(7):623-8. PubMed ID: 18520443
[TBL] [Abstract][Full Text] [Related]
30. Saquinavir/ritonavir monotherapy as a new nucleoside-sparing maintenance strategy in long-term virologically suppressed HIV-infected patients.
Patricia E; Domingo P; Gutierrez M; Gracia M; Fuster M; Molto J; Puig J; Perez-Alvarez N; Clotet B; Negredo E
Curr HIV Res; 2010 Sep; 8(6):467-70. PubMed ID: 20636275
[TBL] [Abstract][Full Text] [Related]
31. MIKADO: a multicentre, open-label pilot study to evaluate the antiretroviral activity and safety of saquinavir with stavudine and zalcitabine.
Katlama C; Pellegrin JL; Lacoste D; Aquilina C; Raffi F; Pialoux G; Vittecoq D; Raguin G; Lantz O; Mouroux M; Calvez V; Trylesinski A; Montestruc F; Dohin E; Goehrs JM; Delfraissy JF
HIV Med; 2001 Jan; 2(1):20-6. PubMed ID: 11737372
[TBL] [Abstract][Full Text] [Related]
32. The rainbow cohort: 96 week follow-up of saquinavir-containing regimens in previously antiretroviral therapy (ART)-naive and pre-treated but protease inhibitor (PI)-naive HIV-infected patients.
Knechten H; Stephan C; Mosthaf FA; Jaeger H; Carganico A; Lutz T; Schewe K; Mayr C; Wolf E; Wellmann E; Tappe A
Eur J Med Res; 2011 Mar; 16(3):93-100. PubMed ID: 21486721
[TBL] [Abstract][Full Text] [Related]
33. Inhibitory quotient as a prognostic factor of response to a salvage antiretroviral therapy containing ritonavir-boosted saquinavir. The CIVSA Study.
Mallolas J; Blanco J; Labarga P; Vergara A; Ocampo A; Sarasa M; Arnedo M; López-Púa Y; García J; Juega J; Guelar A; Terrón A; Dalmau D; García I; Zárraga M; Martínez E; Carné X; Pumarola T; Escayola R; Gatell J
HIV Med; 2007 May; 8(4):226-33. PubMed ID: 17461850
[TBL] [Abstract][Full Text] [Related]
34. Comparison of initial combination antiretroviral therapy with a single protease inhibitor, ritonavir and saquinavir, or efavirenz.
Lucas GM; Chaisson RE; Moore RD
AIDS; 2001 Sep; 15(13):1679-86. PubMed ID: 11546943
[TBL] [Abstract][Full Text] [Related]
35. PI3K/mTOR inhibition prevents anal cancer in mice with established low-grade anal dysplasia.
Gunder LC; Moyer TH; Rademacher BL; Auyueng AS; Leverson G; Zhang W; Matkowskyj KA; Carchman EH
Exp Mol Pathol; 2022 Apr; 125():104752. PubMed ID: 35183509
[TBL] [Abstract][Full Text] [Related]
36. HIV protease genotype and viral sensitivity to HIV protease inhibitors following saquinavir therapy.
Craig C; Race E; Sheldon J; Whittaker L; Gilbert S; Moffatt A; Rose J; Dissanayeke S; Chirn GW; Duncan IB; Cammack N
AIDS; 1998 Sep; 12(13):1611-8. PubMed ID: 9764779
[TBL] [Abstract][Full Text] [Related]
37. The SPICE study: 48-week activity of combinations of saquinavir soft gelatin and nelfinavir with and without nucleoside analogues. Study of Protease Inhibitor Combinations in Europe.
Moyle G; Pozniak A; Opravil M; Clumeck N; DelFraissy JF; Johnson M; Pelgrom J; Reynes J; Vittecoq D; DeLora P; Salgo M; Duff F
J Acquir Immune Defic Syndr; 2000 Feb; 23(2):128-37. PubMed ID: 10737427
[TBL] [Abstract][Full Text] [Related]
38. [A randomized clinical trial to compare the effectiveness of indinavir, ritonavir and saquinavir].
Teira R; Cámara MM; Escobar A; Muñoz P; López de Munain J; Santamaría JM
Med Clin (Barc); 2003 Oct; 121(14):532-4. PubMed ID: 14599408
[TBL] [Abstract][Full Text] [Related]
39. Clinically relevant interpretation of genotype and relationship to plasma drug concentrations for resistance to saquinavir-ritonavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients.
Marcelin AG; Dalban C; Peytavin G; Lamotte C; Agher R; Delaugerre C; Wirden M; Conan F; Dantin S; Katlama C; Costagliola D; Calvez V
Antimicrob Agents Chemother; 2004 Dec; 48(12):4687-92. PubMed ID: 15561845
[TBL] [Abstract][Full Text] [Related]
40. Combination therapy with saquinavir soft gelatin capsules in children with human immunodeficiency virus infection.
Kline MW; Brundage RC; Fletcher CV; Schwarzwald H; Calles NR; Buss NE; Snell P; DeLora P; Eason M; Jorga K; Craig C; Duff F
Pediatr Infect Dis J; 2001 Jul; 20(7):666-71. PubMed ID: 11465838
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
